Regulatory Overview

A Drug Master File (DMF) is a detailed document that records the chemistry, manufacturing, and control (CMC) information of pharmaceutical products. The primary purpose of DMFs is to provide detailed information on drug substances, manufacturing processes, and packaging materials to regulatory agencies like the FDA (USA), PMDA (Japan), EMEA (Europe), and NMPA (China). This ensures the safety, efficacy, and quality of pharmaceuticals.

DMF Classification

In China, the CDE classifies DMFs into two statuses: “A” (Active) and “I” (Inactive). They are further classified into the following types:

Company Obligations and Strategies

Manufacturers of active pharmaceutical ingredients (APIs), excipients, and packaging materials must submit technical information to regulatory bodies in each country. Overseas manufacturers are advised to register through local agents to maintain communication with regulatory authorities.

ClinChoice Services

Providing complete data lists based on DMF application conditions of each country, evaluating product data, and identifying gaps.
Organizing, preparing, and submitting documents according to regulatory requirements in specified formats (e.g., e-CTD). Responding to feedback from regulatory reviews.
Monitoring the progress of reviews and submitting additional required information.
Maintaining DMF numbers and performing necessary annual updates.

ClinChoice Strengths

Multinational team with extensive experience in pharmaceutical regulations, providing registration services for drugs and APIs.
Dedicated technical and business consultants ensuring quick responses.
High-quality service ensured by extensive consulting experience and multilingual support.

Registration Achievements (Up to end of 2023)

China DMF:
22 registrations

USA DMF:
18 registrations

Europe CEP:
8 registrations

Japan JDMF:
2 registrations

Canada DMF:
2 registrations

Korea DMF:
3 registrations